Clinical Trial Update: Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older [Phase 3]

View source ↗

Summary

Phase 3 trial update assessing safety and immunogenicity of different dosing schedules for GSK's herpes zoster vaccine in adults 50+.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• GlaxoSmithKline Herpes Zoster Vaccine (recombinant zoster vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Herpes Zoster | Phase 3 | Status: COMPLETED | Results posted: 2017-03-31